경구 점막 투여제 시장 규모, 점유율, 동향 분석 보고서 : 제형별, 투여 경로별, 치료 용도별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

Oral Transmucosal Drugs Market Summary

The global oral transmucosal drugs market size was valued at USD 37.8 billion in 2025 and is projected to grow from USD 40.5 billion in 2026 to USD 68.5 billion by 2033, at a CAGR of 7.8% from 2026 to 2033. North America dominated the market, accounting for the largest revenue share of 38.6% in 2025. The market is witnessing sustained expansion due to increasing demand for rapid-onset, non-invasive drug delivery systems across pain management, opioid dependence, seizure rescue therapies, and central nervous system disorders.

Pharmaceutical manufacturers are increasingly focusing on sublingual tablets, buccal films, oral thin films, and spray-based formulations that improve bioavailability while bypassing gastrointestinal degradation and first-pass metabolism. Market growth is being further supported by the rising prevalence of chronic neurological disorders, cancer-associated breakthrough pain, and opioid use disorder globally. In addition, the growing preference for needle-free and swallow-free administration among pediatric and geriatric patient populations is accelerating product adoption across both hospital and outpatient settings. Regulatory agencies in the U.S., Europe, and Asia are also supporting innovation through accelerated approvals for advanced transmucosal formulations and specialty drug delivery technologies

The market is increasingly characterized by strong research activity, platform-based drug delivery innovation, and expanding commercialization strategies among pharmaceutical companies. Industry participants are investing heavily in mucoadhesive technologies, permeation enhancers, and advanced oral film platforms to improve drug absorption efficiency and patient adherence. The growing emphasis on convenient self-administration therapies is driving interest in transmucosal delivery for chronic disease management and emergency care applications. In addition, the market is benefiting from rising collaborations between specialty drug delivery developers and pharmaceutical manufacturers aimed at expanding proprietary formulation capabilities and lifecycle management strategies. The increasing adoption of digitally integrated manufacturing technologies and scalable film production systems is also improving production efficiency, supporting broader product availability, and accelerating pipeline development across multiple therapeutic categories.

The market continues to gain momentum due to rising industry focus on temperature-stable oral formulations and ambient-storage drug delivery systems that improve accessibility and supply chain flexibility. Furthermore, growing research in oral peptide delivery, CNS-targeted therapies, and next-generation transmucosal platforms is expected to create substantial long-term commercialization opportunities. Pharmaceutical companies are also expanding investments in patient-centric dosage formats that enhance compliance and reduce administration burden, particularly among elderly and pediatric populations. The increasing penetration of specialty pharmacies, e-commerce pharmaceutical distribution channels, and direct-to-patient delivery models is further strengthening market accessibility. In addition, ongoing advancements in formulation science and biomaterial engineering are expected to support the development of more efficient and targeted transmucosal therapies, contributing to sustained market growth over the forecast period.

Global Oral Transmucosal Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oral transmucosal drugs market report based on dosage form, route of administration, therapeutic application, distribution channel, and region:

• Dosage Form Outlook (Revenue, USD Billion, 2021 - 2033)
• Tablets
• Films
• Lozenges
• Sprays
• Patches & Gels
• Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
• Sublingual
• Buccal
• Other Oral Mucosal Routes
• Therapeutic Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Pain Management
• Opioid Dependence
• Neurological Disorders
• Migraine
• Other Applications
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Dosage Form
  • 1.2.2. Route of Administration
  • 1.2.3. Therapeutic Application
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Oral Transmucosal Drugs Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Oral Transmucosal Drugs Market: Dosage Form Business Analysis

• 4.1. Dosage Form Market Share, 2025 & 2033
• 4.2. Dosage Form Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2021 to 2033 (USD Billion)
• 4.4. Tablets
  • 4.4.1. Tablets Market, 2021 - 2033 (USD Billion)
• 4.5. Films
  • 4.5.1. Films Market, 2021 - 2033 (USD Billion)
• 4.6. Lozenges
  • 4.6.1. Lozenges Market, 2021 - 2033 (USD Billion)
• 4.7. Sprays
  • 4.7.1. Sprays Market, 2021 - 2033 (USD Billion)
• 4.8. Patches & Gels
  • 4.8.1. Patches & Gels Market, 2021 - 2033 (USD Billion)

Chapter 5. Oral Transmucosal Drugs Market: Route of Administration Business Analysis

• 5.1. Route of Administration Market Share, 2025 & 2033
• 5.2. Route of Administration Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
• 5.4. Sublingual
  • 5.4.1. Sublingual Market, 2021 - 2033 (USD Billion)
• 5.5. Buccal
  • 5.5.1. Buccal Market, 2021 - 2033 (USD Billion)
• 5.6. Other Oral Mucosal Routes
  • 5.6.1. Other Oral Mucosal Routes Market, 2021 - 2033 (USD Billion)

Chapter 6. Oral Transmucosal Drugs Market: Therapeutic Application Business Analysis

• 6.1. Therapeutic Application Market Share, 2025 & 2033
• 6.2. Therapeutic Application Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Application, 2021 to 2033 (USD Billion)
• 6.4. Pain Management
  • 6.4.1. Pain Management Market, 2021 - 2033 (USD Billion)
• 6.5. Opioid Dependence
  • 6.5.1. Opioid Dependence Market, 2021 - 2033 (USD Billion)
• 6.6. Neurological Disorders
  • 6.6.1. Neurological Disorders Market, 2021 - 2033 (USD Billion)
• 6.7. Migraine
  • 6.7.1. Migraine Market, 2021 - 2033 (USD Billion)
• 6.8. Other Applications
  • 6.8.1. Other Applications Market, 2021 - 2033 (USD Billion)

Chapter 7. Oral Transmucosal Drugs Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2025 & 2033
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
• 7.6. Online Pharmacies
  • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Billion)

Chapter 8. Oral Transmucosal Drugs Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America Oral Transmucosal Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. Canada Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.5. Europe
  • 8.5.1. Europe Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. UK Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.7. Latin America
  • 8.7.1. Latin America Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Brazil Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. Argentina Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Oral Transmucosal Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Pfizer Inc.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. AbbVie Inc.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Teva Pharmaceutical Industries Ltd.
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Indivior PLC
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Aquestive Therapeutics, Inc.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. BioDelivery Sciences International (Collegium Pharmaceutical)
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. GSK plc
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. Sanofi S.A.
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Novartis AG
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Boehringer Ingelheim International GmbH
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives